Clinical trial · Observational
A Multi-omics-based Metabolic Typing Study of Gastric Cancer
Clinical Study on Metabolic Typing of Gastric Cancer Based on Transcriptome, Metabolome and Other Multi-omics
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the study, the investigators obtained gastric cancer tissues from 480 gastric cancer patients who had undergone surgery at the Zhejiang Cancer Hospital's biospecimen bank between 2012-2019, and obtained relevant clinical information. The gastric cancer tissues were subjected to transcriptomic, metabolomic and other multi-omics testing, and analyzed for the metabolic changes of gastric cancer, and proposed to discover relevant therapeutic targets.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diagnosis | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Multi-omics | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Without any intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cancer tissues
- interventionNames
- Other: Without any intervention
- label
- Normal adjacent tissues
- interventionNames
- Other: Without any intervention
Primary outcomes (1)
- measure
- The differences of the metabolism information
- timeFrame
- through study completion, an average of 6 months
- description
- The differences of the metabolism information between gastric cancer tissues and non-cancerous gastric cancer tissues. These data included Metabolizing enzyme mRNA expression and metabolite content.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * 18≤age≤80 * Histologically or cytologically confirmed gastric cancer * Undergo surgery for radical or palliative gastric cancer (both open and laparoscopic) * Patients with survival follow-up information Exclusion Criteria: * Two or more kinds of malignant tumors at the same time * Incomplete or missing case information * Preoperative diagnosis of residual gastric cancer
References
Publications (3)
- RESULTLi S, Yuan L, Xu ZY, Xu JL, Chen GP, Guan X, Pan GZ, Hu C, Dong J, Du YA, Yang LT, Ni MW, Jiang RB, Zhu X, Lv H, Xu HD, Zhang SJ, Qin JJ, Cheng XD. Integrative proteomic characterization of adenocarcinoma of esophagogastric junction. Nat Commun. 2023 Feb 11;14(1):778. doi: 10.1038/s41467-023-36462-8. PMID 36774361
- RESULTShi W, Wang Y, Xu C, Li Y, Ge S, Bai B, Zhang K, Wang Y, Zheng N, Wang J, Wang S, Ji G, Li J, Nie Y, Liang W, Wu X, Cui J, Wang Y, Chen L, Zhao Q, Shen L, He F, Qin J, Ding C. Multilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer. Nat Commun. 2023 Feb 14;14(1):835. doi: 10.1038/s41467-023-35797-6. PMID 36788224
- RESULTWang J, Kunzke T, Prade VM, Shen J, Buck A, Feuchtinger A, Haffner I, Luber B, Liu DHW, Langer R, Lordick F, Sun N, Walch A. Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients. Clin Cancer Res. 2022 Jul 1;28(13):2865-2877. doi: 10.1158/1078-0432.CCR-21-4383. PMID 35395077